NASDAQ:HROW - Harrow Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 145.10 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.14
▼ -0.14 (-1.92%)

This chart shows the closing price for HROW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harrow Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HROW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HROW

Analyst Price Target is $17.50
▲ +145.10% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Harrow Health in the last 3 months. The average price target is $17.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 145.10% upside from the last price of $7.14.

This chart shows the closing price for HROW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Harrow Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2022B. RileyBoost Price TargetBuy$17.00 ➝ $20.00High
10/14/2021B. RileyInitiated CoverageBuy$16.00Medium
9/23/2021AegisInitiated CoverageBuy$15.00High
7/2/2021LADENBURG THALM/SH SHInitiated CoverageBuy$14.25Medium
5/12/2021B. RileyBoost Price TargetBuy$14.00 ➝ $15.00High
1/4/2021B. RileyBoost Price TargetOutperform ➝ Buy$12.00 ➝ $14.00N/A
4/7/2020B. RileyLower Price TargetBuy$12.00 ➝ $10.00Low
3/16/2020B. RileyLower Price TargetBuy$12.75 ➝ $12.00High
8/16/2019Lake Street CapitalSet Price TargetBuy$15.00Low
12/13/2018B. RileyInitiated CoverageBuy ➝ Buy$11.50High
12/10/2018Lake Street CapitalInitiated CoverageBuy ➝ Buy$10.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/6/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Harrow Health logo
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.14
Low: $7.08
High: $7.31

50 Day Range

MA: $6.71
Low: $5.75
High: $7.74

52 Week Range

Now: $7.14
Low: $5.40
High: $12.99

Volume

1,354 shs

Average Volume

95,545 shs

Market Capitalization

$193.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Harrow Health?

The following Wall Street analysts have issued reports on Harrow Health in the last twelve months: Aegis, B. Riley, and TheStreet.
View the latest analyst ratings for HROW.

What is the current price target for Harrow Health?

0 Wall Street analysts have set twelve-month price targets for Harrow Health in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 145.1%.
View the latest price targets for HROW.

What is the current consensus analyst rating for Harrow Health?

Harrow Health currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HROW will outperform the market and that investors should add to their positions of Harrow Health.
View the latest ratings for HROW.

How do I contact Harrow Health's investor relations team?

Harrow Health's physical mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company's listed phone number is (615) 733-4730 and its investor relations email address is [email protected] The official website for Harrow Health is www.harrowinc.com. Learn More about contacing Harrow Health investor relations.